Sequentially weaker 3Q13 as anticipated. 3Q13 net profit of USD3.1m (-63% QoQ) was a function of weaker revenue of USD17.3m (-22% QoQ) and a one-time tax charge of USD2.6m. The 3Q13 performance was affected by a slowdown in the Indian diamond manufacturing sector, which was hit by: (1) weakened INR, (2) tightened credit conditions, and (3) margin squeeze for manufacturers on high rough diamond prices.
Galaxy deliveries slower but continues to increase. Only 5 Galaxy systems were delivered in 3Q13 (2Q13: 17, 3Q12: 5), bringing total installed base to 127. Recurring revenue accounted for ~30% of 9M13 revenue, mitigating volatility in capital equipment sales.
New revenue drivers progressing. There was maiden contribution from Sarine Light (TM) this quarter which was insignificant, but importantly, more retail chains in Japan have begun adopting the system. Sarin intends to launch this product in Hong Kong and Taiwan by 1Q14. The Sarine Loupe (TM) will also be introduced to select manufacturers in India after the Divali holiday before its commercial launch in 2014.
Hiccups temporal; expect a strong earnings recovery year in 2014. 4Q13 may continue to be weighed down by operational headwinds confronting the Indian manufacturing sector but we expect a sequential improvement as the operating environment has improved. This should also pave the way for a strong earnings growth year in 2014. We cut our FY13-15 forecasts marginally by up to 1.2%.
TP raised to SGD2.16, reiterate Buy. Sarin's stock price has appreciated by 17% since 2Q13 results despite weaker guidance for 3Q13. We still see a strong long-term investment case for Sarin. We see potential earnings kicker from its new product launches, implying room for positive earnings surprises. We raise our TP to SGD 2.16, based on 15x FY14 PER (previously 13x). We believe that our valuation is fair considering its 31% EPS CAGR and high ROEs of 40-50% over FY13-15. In comparison, diamond miners and retailers trade at average PERs of 14x and 26x respectively. Reiterate Buy.
Source: Maybank Kim Eng Research - 5 Nov 2013
Chart | Stock Name | Last | Change | Volume |
---|
Created by kimeng | Dec 29, 2022
Created by kimeng | Dec 29, 2022
Peter Graham Lancashire
Like Sarin for its growth potential and high ROE backed up by "proprietary"positions i.e.patents,and innovative new products still with roll out to come. India is a concern and the impact hard to decipher for ordinary mortals! PGL
2013-11-06 02:10